In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 4, 2010, Pages 697-706

  Ozbay, Tuba ^a   Durden, Donald L ^a   Liu, Tongrui ^a   O'Regan, Ruth M ^a   Nahta, Rita ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug resistance; Herceptin; PI3 kinase; Targeted therapy

Indexed keywords

[1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; AGAR; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INOSITOL PHOSPHATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; SURVIVIN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MICROTUBULE ASSOCIATED PROTEIN; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLIGOPEPTIDE; PHOSPHATIDYLINOSITOL 3 KINASE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG SENSITIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GASTROINTESTINAL TRACT FUNCTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL CYCLE G1 PHASE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RESISTANCE; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INHIBITORS; FLOW CYTOMETRY; G1 PHASE; HUMANS; IMMUNOBLOTTING; MICROTUBULE-ASSOCIATED PROTEINS; OLIGOPEPTIDES; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2;

EID: 75749091464     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1075-9     Document Type: Article

References (27)

1. DJ Slamon GM Clark SG Wong, et al. 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D 3798106
2. P Carter L Presta CM Gorman, et al. 1992 Humanization of an anti-p185HER2 antibody for human cancer treatment Proc Natl Acad Sci USA 89 4285 4289 10.1073/pnas.89.10.4285 1:CAS:528:DyaK3sXitFSqtb0%3D 1350088
3. J Baselga D Tripathy J Mendelsohn, et al. 1996 Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer J Clin Oncol 14 737 744 1:CAS:528:DyaK28Xit1Gjs7w%3D 8622019
4. MA Cobleigh CL Vogel D Tripathy, et al. 1999 Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progresssed after chemotherapy for metastatic disease J Clin Oncol 17 2639 2648 1:CAS:528:DyaK1MXmtlWrurk%3D 10561337
5. CL Vogel MA Cobleigh D Tripathy, et al. 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719 726 10.1200/JCO.20.3.719 1:CAS:528:DC%2BD38XhsVGmt7o%3D 11821453 (Pubitemid 34111379)
6. FJ Esteva V Valero D Booser, et al. 2002 Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer J Clin Oncol 20 1800 1808 10.1200/JCO.2002.07.058 1:CAS:528:DC%2BD38XjtFGqsrw%3D 11919237 (Pubitemid 34273269)
7. FM Yakes W Chinratanalab CA Ritter, et al. 2002 Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action Cancer Res 62 4132 4141 1:CAS:528:DC%2BD38XlsV2ltr0%3D 12124352
8. Y Nagata KH Lan X Zhou, et al. 2004 PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 117 127 10.1016/j.ccr.2004.06.022 1:CAS:528: DC%2BD2cXns1arsr8%3D 15324695 (Pubitemid 39485684)
9. K Berns HM Horlings BT Hennessy, et al. 2007 A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer Cancer Cell 12 395 402 10.1016/j.ccr.2007.08.030 1:CAS:528:DC%2BD2sXht1ais7zL 17936563 (Pubitemid 47539306)
10. L Yang HC Dan M Sun, et al. 2004 Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt Cancer Res 64 4394 4399 10.1158/0008-5472.CAN-04-0343 1:CAS:528:DC%2BD2cXltlOrs74%3D 15231645 (Pubitemid 38856907)
11. CH Lu SL Wyszomierski LM Tseng, et al. 2007 Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency Clin Cancer Res 13 5883 5888 10.1158/1078-0432.CCR-06-2837 1:CAS:528:DC%2BD2sXhtFSntLvJ 17908983 (Pubitemid 47583915)
12. R Nahta T Takahashi NT Ueno, et al. 2004 P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells Cancer Res 64 3981 3986 10.1158/0008-5472.CAN-03-3900 1:CAS:528:DC%2BD2cXksVKns7k%3D 15173011 (Pubitemid 38697313)
13. DL Rowe T Ozbay LM Bender R Nahta 2008 Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer Mol Cancer Ther 7 1900 1908 10.1158/1535-7163.MCT-08-0012 1:CAS:528:DC%2BD1cXoslCgtbs%3D 18645000
14. JR Garlich P De N Dey, et al. 2008 A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity Cancer Res 68 206 215 10.1158/0008-5472.CAN-07-0669 1:CAS:528:DC%2BD1cXoslSn 18172313
15. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 10.1016/0065-2571(84)90007-4 1:CAS:528:DyaL2cXktlaksLk%3D 6382953
16. I Burvenich S Schoonooghe L Vervoort C Dumolyn E Coene L Vanwalleghem J Van Huysse M Praet C Cuvelier N Mertens F De Vos G Slegers 2008 Monoclonal antibody 14C5 targets integrin alphavbeta5 Mol Cancer Ther 7 3771 3779 10.1158/1535-7163.MCT-08-0600 1:CAS:528:DC%2BD1cXhsV2iurbM 19074852
17. RC Castellino DL Durden 2007 Mechanisms of disease: the PI3K-Akt-PTEN signaling node-an intercept point for the control of angiogenesis in brain tumors Nat Clin Pract Neurol 3 682 693 10.1038/ncpneuro0661 1:CAS:528: DC%2BD2sXhtlKltLrM 18046441 (Pubitemid 350238060)
18. CA Ritter M Perez-Torres C Rinehart, et al. 2007 Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network Clin Cancer Res 13 4909 4919 10.1158/1078-0432.CCR-07-0701 1:CAS:528:DC%2BD2sXptVGmtLg%3D 17699871 (Pubitemid 47294799)
19. Y Lu X Zi Y Zhao, et al. 2001 Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J Natl Cancer Inst 93 1852 1857 10.1093/jnci/93.24.1852 1:CAS:528:DC%2BD38XltVWluw%3D%3D 11752009
20. R Nahta LX Yuan B Zhang, et al. 2005 Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells Cancer Res 65 11118 11128 10.1158/0008-5472.CAN-04-3841 1:CAS:528:DC%2BD2MXht1KjsrrI 16322262 (Pubitemid 41713383)
21. André F, Campone M, Hurvitz SA et al (2008) Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol 26:May 20 suppl abstr 1003
22. GE Konecny MD Pegram N Venkatesan, et al. 2006 Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells Cancer Res 66 1630 1639 10.1158/0008-5472.CAN-05-1182 1:CAS:528:DC%2BD28XpsVemsg%3D%3D 16452222 (Pubitemid 43259947)
23. R Nahta LX Yuan Y Du, et al. 2007 Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling Mol Cancer Ther 6 667 674 10.1158/1535-7163.MCT-06-0423 1:CAS:528:DC%2BD2sXhvVWrsbc%3D 17308062 (Pubitemid 46332467)
24. O'Shaughnessy J, Blackwell KL, Burstein H et al (2008) A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 26:May 20 suppl abstr 1015
25. R Nahta MC Hung FJ Esteva 2004 The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells Cancer Res 64 2343 2346 10.1158/0008-5472.CAN-03-3856 1:CAS:528: DC%2BD2cXis1yjt7k%3D 15059883 (Pubitemid 38523885)
26. Gelmon KA, Fumoleau P, Verma S et al (2008) Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J Clin Oncol 26:May 20 suppl; abstr 1026
27. F Cardoso V Durbecq JF Laes, et al. 2006 Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner Mol Cancer Ther 5 3042 3051 10.1158/1535-7163.MCT-06-0104 1:CAS:528:DC%2BD28XhtlagsbrM 17148762 (Pubitemid 46092045)